Skip to main content

Table 4 Adjusted odds ratios and 95% confidence intervals for prescribing vs. not prescribing a drug based on receiving any payment vs. no payment from the manufacturer making the druga

From: Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

Drug Manufacturer Odds Ratio 95% Confidence Interval
Lovastatin ER Actavis (Andrx) 2.59 0.93–7.18
Almotriptan Janssen 1.40 0.75–2.61
Amlodipine+olmesartan Daiichi-Sankyo 2.40 2.29–2.52
Ibuprofen+famotidine Horizon 8.06 5.42–12.00
Saxagliptin+metformin AstraZeneca 2.21 2.10–2.34
Naproxen+esomeprazole Horizon 5.96 5.08–7.00
  1. aadjusted for gender, specialty, region, therapeutic category and overall prescribing volume
  2. p-value <0.05 are presented in boldface